Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
TweRJ72mWNRt9HGJ